Risteys · N14_VULVAL_DYSPLASIA

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule only females	293373
2. Check conditions None	293373
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — N90.3 Cause of death: ICD-10 — N90.3 2 out of 7 registries used, show all original rules.	52
4. Check minimum number of events None	52
5. Include endpoints None	52
6. Filter based on genotype QC (FinnGen only)	52

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	290	290	-
Only index persons	280	280	-
Unadjusted period prevalence (%)
Whole population	0.01	0.01	-
Only index persons	0.01	0.01	-
Median age at first event (years)
Whole population	-	59.03	-
Only index persons	-	58.75	-

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	52	52	-
Unadjusted period prevalence (%)	0.02	0.02	-
Median age at first event (years)	56.48	56.48	-

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3025130) Human papilloma virus identified in Specimen

32.04

12.49

1.9

2.1

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

6.62

7.73

2.5

1.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

3.42

4.38

4.5

3.6

—

(3023368) Bacteria identified in Blood by Culture

3.19

3.81

3.8

3.7

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

137

3.02

3.71

1.9

1.4

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

3.17

3.25

3.7

2.5

e6/l

1.7

1.1

—

(4035726)

3.50

3.10

1.3

—

(40768804) Tissue Pathology biopsy report

191

2.76

3.09

4.4

2.1

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.83

3.06

2.2

1.8

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

9.04

2.81

1.0

1.3

—

(36304419) Bacteria [Presence] in Urine

108

2.58

2.64

4.9

2.5

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

2.93

2.64

3.8

2.7

e6/l

2.4

5.4

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

220

2.58

2.64

5.4

5.9

mmol/l

1.2

0.30

186

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

132

2.52

2.63

5.1

2.6

—

(3002582) Erythrocytes [#/volume] in Urine

125

2.51

2.57

4.4

2.6

e6/l

15.8

28.2

0.60

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

103

2.53

2.49

1.7

1.3

iu/ml

12.2

31.4

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.02

2.48

1.4

1.3

—

(3026782) Osmolality of Urine

2.74

2.46

4.2

2.3

mosm/kgh2o

455.6

499.7

0.35

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

3.13

2.46

1.6

1.8

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

6.77

2.42

1.0

1.3

—

(3044640) Blood type and Crossmatch panel - Blood

137

2.40

2.38

2.5

1.8

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

4.69

2.22

1.0

1.1

—

(3052851) Hemolysis interference index of Serum or Plasma

5.40

2.12

5.0

4.8

—

(42870588) Differential panel, method unspecified - Blood

143

2.26

2.11

9.0

4.9

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

4.90

1.99

1.0

1.5

—

(3031040) Bacteria [#/volume] in Urine by Automated count

311

2.50

1.96

6.0

4.4

—

111.0

—

(3018095) Leukocytes [#/volume] in Urine

147

2.17

1.94

5.7

3.3

e6/l

17.7

76.3

1.33

103

(3042936) Bacteria identified in Isolate by Culture

2.59

1.91

2.2

1.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.81

1.84

1.8

1.7

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.54

1.84

1.8

1.7

—

(3000492) Spirometry study

2.96

1.81

1.5

1.4

—

(3002256) Pathology report gross observation

2.44

1.71

1.3

1.2

—

(40758558) Short blood count panel - Blood

119

2.11

1.70

6.5

—

(3026493) Urate [Moles/volume] in Serum or Plasma

105

2.09

1.60

1.7

2.1

umol/l

274.3

9242.7

1.08

(36660697) Celiac disease serology panel - Serum

2.73

1.57

1.1

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.73

1.57

1.8

1.7

—

(3037467) Urinalysis macro (dipstick) panel - Urine

314

2.19

1.55

6.1

4.2

—

(3026008) Bacteria identified in Urine by Culture

158

1.96

1.52

3.2

2.7

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.73

1.51

1.4

1.3

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

2.44

1.46

3.2

4.0

u/l

222.2

249.0

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

3.14

1.39

4.8

2.2

mmol/l

23.6

24.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.34

1.38

1.4

—

(3015736) pH of Urine

181

1.87

1.37

6.0

3.5

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.69

1.34

1.2

2.0

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

2.11

1.34

1.5

1.6

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

2.96

1.31

5.0

2.1

g/l

126.4

127.5

—

(40768797) Stomach Pathology biopsy report

2.14

1.31

1.3

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

2.47

1.22

4.3

2.3

kpa

5.1

5.6

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

2.65

1.18

1.4

1.5

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

218

1.75

1.12

6.1

4.0

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

109

1.83

1.12

1.9

1.3

u/ml

54.1

15.6

—

(3003694) ABO and Rh group [Type] in Blood

136

1.76

1.08

1.8

1.4

—

(3009542) Hematocrit [Volume Fraction] of Blood

418

2.29

1.03

21.5

12.3

39.7

39.9

0.10

304

(40761535) Cells panel - Urine sediment

2.20

0.93

8.7

2.9

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

1.99

0.85

1.3

1.1

—

174.7

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

2.19

0.77

1.2

1.4

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

1.94

0.70

1.0

1.3

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

170

1.51

0.67

2.4

1.8

pmol/l

74.5

108.4

—

(3003338) MCHC [Mass/volume]

396

1.72

0.65

29.7

15.0

g/l

329.6

330.6

0.40

396

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

290

1.50

0.63

3.3

3.1

—

(3012544) pH of Venous blood

1.74

0.63

2.6

2.2

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

1.74

0.63

1.0

1.2

—

(3000494) Fungus identified in Specimen by Culture

1.60

0.62

1.6

1.2

—

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

0.00

0.61

0.0

1.5

—

286.2

—

(40760892) CBC W Ordered Manual Differential panel - Blood

119

1.50

0.57

5.1

3.9

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

130

1.46

0.53

3.2

1.9

u/l

127.1

135.3

0.05

124

(3051387) C reactive protein [Mass/volume] in Capillary blood

0.00

0.42

0.0

4.9

—

18.3

—

(3017044) Thyrotropin receptor Ab [Units/volume] in Serum

0.00

0.41

0.0

1.6

—

7.8

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.42

0.40

1.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

185

1.33

0.38

6.7

3.9

—

(3013512) EKG study

132

0.70

0.38

4.1

3.0

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.45

0.36

1.3

1.6

—

(3019309) Folate [Moles/volume] in Red Blood Cells

1.26

0.27

1.4

1.7

nmol/l

1865.4

1190.7

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.35

0.24

1.2

1.4

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.21

0.22

4.4

3.0

—

(3022621) pH of Urine by Test strip

1.21

0.22

1.4

2.8

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.21

0.0

4.5

—

1.5

—

(3004616) Nuclear Ab [Presence] in Serum

0.00

0.21

0.0

1.1

—

(3022313) Gas panel - Capillary blood

0.00

0.21

0.0

4.5

—

(4281824)

0.00

0.21

0.0

1.0

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

0.00

0.21

0.0

2.6

—

4.2

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

0.00

0.21

0.0

2.6

—

61.9

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.21

0.0

3.3

—

137.5

—

(3022145) Colonoscopy Study observation

1.15

0.18

1.9

1.3

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.73

0.18

1.8

1.9

—

(3044889) 12 lead EKG panel

323

1.15

0.12

6.0

3.3

—

(3032080) INR in Blood by Coagulation assay

154

1.15

0.12

8.8

5.9

inr

1.1

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.20

0.12

1.8

1.7

—

(1761868) Lipid panel - Serum or Plasma

166

0.86

0.12

2.3

2.7

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

165

0.87

0.10

9.1

3.1

ng/l

11.8

20.3

—

105

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

431

1.14

0.07

19.5

10.6

ml/min/173m2

83.5

82.8

0.10

341

(3041096) Erythrocytes [Presence] in Urine by Automated

133

1.07

0.02

5.3

3.7

—

(40760888) Immunoglobulin light chains.free panel - Serum

0.00

0.0

3.1

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

0.00

0.0

1.0

—

32.5

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

1.02

0.00

1.4

1.9

27.0

28.6

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

25.4

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.0

1.2

—

(40759836) Histone Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

0.00

0.0

1.0

—

34.5

—

(4306422)

0.00

0.0

1.2

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

1.1

—

(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

96.7

—

(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum

0.00

0.0

3.6

—

(3019897) Erythrocyte distribution width [Ratio] by Automated count

0.00

0.0

1.0

—

13.8

—

(4211845)

0.00

0.0

1.4

—

(4146454)

0.00

0.0

2.8

—

(40768795) Lymph node Pathology biopsy report

0.00

0.0

1.0

—

(3019539) Treponema pallidum Ab [Titer] in Serum by Hemagglutination

0.00

0.0

1.2

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

0.00

0.0

1.1

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

0.00

0.0

2.1

—

105.0

—

(3045156) Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

0.0

2.6

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.85

0.00

3.0

5.6

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

2.6

—

207.0

—

(40766048) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.2

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

0.00

0.0

1.0

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3022803) Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

0.0

2.6

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.0

1.1

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

1.8

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.0

4.6

—

24.7

—

Mortality – FinRegistry

↥

Association

Association between endpoint N14_VULVAL_DYSPLASIA_NOS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have N14_VULVAL_DYSPLASIA_NOS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: N14_VULVAL_DYSPLASIA_NOS – Dysplastic lesion of the vulva of unknown severity

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	N14_VULVAL_DYSPLASIA_NOS
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX	2
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	N903
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	N903
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Dysplastic lesion of the vulva of unknown severity

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints